Respiratory Syncytial Virus (RSV)

Respiratory syncytial virus is a common respiratory virus causing mild cold-like symptoms in most people but potentially serious lung infections
(bronchiolitis and pneumonia) in infants, older adults, and immunocompromised individuals.

Featured product

Real World Evidence Impact of universal immunization with
Nirsevimab

Explore real-world evidence on nirsevimab effectiveness and safety in RSV prevention, for HCP decision support.

Learn more

Latest Articles

See all articles

Article

Jul 7, 2026

RSV Prevention Guidelines in KSA

Long-acting Monoclonal Antibody is now mandatory for all infants in KSA

Learn more

Article

Jul 7, 2026

RSV Prevention Guidelines in UAE

Long acting Monoclonal Antibody is now mandatory for all infants in UAE

Learn more

Article

Apr 24, 2026

Real-World Effectiveness of Nirsevimab

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Learn more

Latest Resources

See all resources

Resource

Nov 19, 2025

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

Learn more

Resource

Nov 19, 2025

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Learn more

Resource

Nov 12, 2025

An easy guide to use Nirsevimab

Nirsevimab is given for infants entering their first RSV season as a single injection based on infant's weight at the time of dosing

Learn more

MAT-BH-2600336-v1-June-2026